Saratov JOURNAL of Medical and Scientific Research
Home

Evaluation of soluble fms-like thyroxine kinase-1 and endo-thelial antibodies in patients with acute coronary syndrome in the post-COVID period

Year: 2024, volume 20 Issue: №4 Pages: 414-419
Heading: Cardiology Article type: Original article
Authors: Kozik V.A., Shpagina L.A., Shpagin I.S., Loktin E.M.
Organization: Novosibirsk State University
Summary:

Objective: to evaluate the role of soluble fms-like thyroxine kinase-1 and endothelial factor in patients with acute coronary syndrome in the post-COVID period. Material and methods. The study included 118 patients (including 57 women and 61 men) with acute coronary syndrome and COVID-19 history. Soluble fms-like thyroxine kinase-1 and endothelial factor were determined in all patients. The comparison group consisted of 121 patients with acute coronary syndrome without COVID-19. Results. High levels of soluble fms-like thyroxine kinase-1 and antibodies to endothe-lium were more often detected in the ACS and previous COVID-19 group than in the comparison group (risk ratio — RR=2.768 [95% confidence interval — Cl: 2.0810-3.681]; p<0.001) and (RR=1,554 [95% Cl: 1.216-1.987]; p=0.002), respectively. In the group of patients with ACS and COVID-19, a more severe course of ACS was also observed: rhythm disturbances were recorded more often (RR=1.372 [95% Cl: 1.005-1.784]; p=0.032), rehospitalization in the first 14 days for cardiovascular diseases (RR=1.475 [95% Cl: 1.100-1.977]; p=0.032) and hospital mortality (RR=1.610 [95% Cl: 1.160-2.233]; p=0.042). Conclusion. The obtained data allow us to say that anti-endothelial antibodies and soluble fms-like thyroxine kinase-1 are associated with the risk of developing severe ACS in patients with COVID-19 history.

Keywords: acute coronary syndrome, antiendothelial antibodies, new coronavirus infection, post-COVID period, soluble fms-like thyroxine kinase-1

Bibliography:
1. Alekyan BG, Boytsov SA, Ganyukov VI, et al. Impact of the COVID-19 pandemic on myocardial revascularization in patients with acute coronary syndrome in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2022; (4): 411-9. DOI: 10.20996/1819-6446-2022-08-03
2. Shao НН, Yin RX. Pathogenic mechanisms of cardiovascular damage in COVID-19. Mol Med. 2024; (1): 92. DOI: 10.1186/s10020-024-00855-2
3. JassatW, Reyes LF, Munblit D, et al. Long COVID in low-income and middle-income countries: the hidden public health crisis. Lancet. 2023; 402 (10408): 1115-7. DOI: 10.1016/S0140-6736(23)01685-9
4. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020; 24: 1-8. DOI: 10.1186/s13054-020-03062-7
5. Evans PC, Rainger GE, Mason J О et al. Endothelial dysfunction in COVID-19: A position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020; 116 (14): 2177-84. DOI: 10.1093/cvr/cvaa230
6. Selvarajan S, Ramalingam J, Venugopal V Soluble FMS-like tyrosine kinase-1: An overview. Int J Med Biochem. 2023; 6 (2):117-23. DOI: 10.14744/ijmb.2023.66933
7. Droge LA, Perschel FH, Stutz N, et al. Prediction of preeclampsia-related adverse outcomes with the sFLT-1 (soluble fms-like tyrosine kinase 1)/PIGF (placental growth factor) — ratio in the clinical routine: A real-world study. Hypertension. 2021; 77 (2): 461-71. DOI: 10.1161/hypertensionaha.120.15146
8. Kadife E, Hannan N, Harper A, et al. Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro. PLoS One. 2022; 17 (11): e0271560. DOI: 10.1371/journal.pone. 0271560
9. Wada H, Shinozaki T, Suzuki M, et al. Impact of chronic kidney disease on the Associations of Cardiovascular Biomark-ers with adverse outcomes in patients with suspected or known coronary artery disease: The EXCEED-J Study. J Am Heart As-soc. 2022; 11 (3): e023464. DOI: 10.1161/JAHA.121.023464
10. Eguiburu-Jaime JL, Delmiro A, Lalueza A, et al. Soluble fms-like tyrosine kinase-1: A potential early predictor of respiratory failure in COVID-19 patients. Clin Chem Lab Med. 2021; 59 (7): e289-92. DOI:10.1515/cclm-2021-0126
11. Dupont V, Kanagaratnam L, Goury A, et al. Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill coronavirus disease 2019 patients. Clin Infect Dis. 2021; 72 (10): 1834-7. DOI: 10.1093/cid/ciaa1007
12. Servettaz A, Guilpain P, Tamas N, et al. Natural anti-endothelial cell antibodies. Autoimmun Rev. 2008; 7 (6): 426-30. DOI: 10.1016/j.autrev.2008.03.010
13. Meroni P, Ronda N, Raschi E, et al. Humoral autoimmunity against endothelium: Theory or reality? TRENDS in Immunology. 2005; 26 (5): 275-81. DOI: 10.1016/j.it.2005.03.006
14. Farsi A, Domeneghetti MP, Brunelli T, et al. Activation of the immune system and coronary artery disease: The role of anti-endothelial cell antibodies. Atherosclerosis. 2001; 154 (2): 429-36. DOI: 10.1016/s0021 -9150(00)00482-2
15. On the Strategy for Scientific and Technological Development of the Russian Federation: Decree of the President of the Russian Federation No. 145 dated 28.02.2024. URL: https://www.garant.ru/products/ipo/prime/doc/408518353/7ysc Iid=m4mxwm76vg240414981 (28 Feb 2024).
16. Features of long-COVID infection clinical course. Therapeutic and rehabilitation measures. Methodological recommendations. Terapiya = Therapy. 2022; 1 (Suppl): 1-147DOI: 10.18565/ therapy.2022.1suppl.1-147
17. Temporary clinical guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19), version 18 (October 26, 2023). Approved by the Ministry of Health of the Russian Federation, 2023. URL: https://static-0.minzdrav.gov.ru/system/attachments/attach-es/000/064/610/original/BMP_COVID-19_V18.pdf (20 Oct 2024).
18. Barbarash OL, Duplyakov DV, Zateyshchikov DA, et al. Acute coronary syndrome without ST segment elevation of the electrocardiogram. Clinical recommendations 2020. Russ J Car-diol. 2021: 26 (4): 149-202. DOI: 10.15829/1560-4071-2021-4449
19. Negro A, Fama A, Penna D, et al. SFLT-1 levels in CO-VID-19 patients: Association with outcome and thrombosis. Am J Hematol. 2021; (2): 41-43. DOI: 10.1002/ajh.26037.
20. Alfaro E, Diaz-Garcia E, Garcia-Tovar S, et al. Endothe-lial dysfunction and persistent inflammation in severe post-COV-ID-19 patients: Implications for gas exchange. ВМС Med. 2024; (1): 242. DOI: 10.1186/s12916-024-03461-5

AttachmentSize
2024_04_414-419.pdf376.87 KB
All articles of the authors: Kozik V.A., Loktin E.M., Shpagin I.S., Shpagina L.A.

No votes yet